Results 31 to 40 of about 12,992 (201)

Comparison of demographic and outcome in the Brazilian aHUS cohort patients according to the treatment (without the use of Eculizumab, prophylactic Eculizumab, and Eculizumab treatment).

, 2021
Comparison of demographic and outcome in the Brazilian aHUS cohort patients according to the treatment (without the use of Eculizumab, prophylactic Eculizumab, and Eculizumab treatment).
Hong Si Nga (4592092), Valter Duro Garcia (5221406), Lilian Monteiro Pereira Palma (4592095), Luis Gustavo Modelli de Andrade (4592089), Roger Kist (7528070), Pedro Augusto Macedo de Souza (11663289), Ida Maria Maximina Fernandes-Charpiot (7586720), Miguel Ernandes Neto (11663283), Silvana Maria Carvalho Miranda (11663286), Gerson Marques Pereira Jr (11663292)   +9 more
core   +1 more source

Cumulative incidence of TMA graft loss (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).

, 2021
Cumulative incidence of TMA graft loss (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).
Hong Si Nga (4592092), Valter Duro Garcia (5221406), Lilian Monteiro Pereira Palma (4592095), Luis Gustavo Modelli de Andrade (4592089), Roger Kist (7528070), Pedro Augusto Macedo de Souza (11663289), Ida Maria Maximina Fernandes-Charpiot (7586720), Miguel Ernandes Neto (11663283), Silvana Maria Carvalho Miranda (11663286), Gerson Marques Pereira Jr (11663292)   +9 more
core   +1 more source

Eculizumab in Pediatric Kidney Disorders: A Review: Eculizumab in Kidney Disorders

, 2022
Eculizumab is a humanized monoclonal antibody targeting the C5 (complement 5) memberof complement proteins and inhibiting its cleavage to C5a and C5b. Eculizumab has beenproven to be effective in a wide array of nephrologic, neurologic, and hematologic ...
Mohkam, Masoumeh, Akhondi, Amir Hossein, Kamali, Farnaz, Jamee, Mahnaz, Hajialigol, Amir Hossein, Farsi, Yeganeh, Mirzaee, Mahbubeh   +6 more
core   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings [PDF]

, 2011
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated with defective regulation of the alternative complement pathway.
Sibylle Tschumi, Tschumi, Sibylle, Simonetti, Giacomo D, Giacomo D. Simonetti, Magdalena Riedl, Barbara S. Bucher, Bucher, Barbara S, Gugger, Mathias, Riedl, Magdalena, Mathias Gugger   +9 more
core   +2 more sources

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD

, 2021
Objective: During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD).
Berthele, A, Oreja-Guevara, C, Sabatella, G, Nakashima, I, Fujihara, K, Miller, L, Kim, HJ, Yountz, M, Winkel, Antony, Palace, J, Wingerchuk, DM, Levy, M, Pittock, SJ, Shang, S, Wang, KC, et al.   +15 more
core   +1 more source

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis

Frontiers in Medicine, 2023
Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic abnormalities, infections, autoimmune diseases, drugs, and malignancies.
Sanober Sadiq, Anatoly Urisman, Onur Cil
doaj   +1 more source

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal [PDF]

, 2021
Contains fulltext : 241453.pdf (Publisher’s version ) (Open Access)BACKGROUND: The introduction of eculizumab has significantly improved the outcome of patients with atypical haemolytic uraemic syndrome (aHUS).
van der Heijden, Joost W., Heijden, J.W. van der, Kar, N.C.A.J. van de, van de Kar, Nicole C. A. J., Duineveld, Caroline, Wetzels, Jack F. M., Bouwmeester, Romy, Bouwmeester, R.N., Berger, S.P., Wetzels, J., Duineveld, C., Berger, Stefan P.   +11 more
core   +2 more sources

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy

Frontiers in Pediatrics, 2021
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT) associated with high morbidity and mortality. High-risk TA-TMA (hrTA-TMA) is characterized by multifactorial
Laura Gomez-Ganda, Maria Isabel Benitez-Carabante, Aurora Fernandez-Polo, Marina Muñoz-Lopez, Berta Renedo-Miro, Gema Ariceta, Cristina Diaz De Heredia   +6 more
doaj   +1 more source

Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy [PDF]

, 2019
The complement inhibitor, eculizumab, has revolutionised the management of atypical haemolytic uraemic syndrome (aHUS), although the optimum treatment duration is debated.
Shah, R, Scully, M, Neave, L, Gale, DP, Cheesman, S   +4 more
core   +2 more sources